Helus Pharma (HELP) said Wednesday that enrollment in its phase 3 clinical trial evaluating HLP003 for the adjunctive treatment of major depressive disorder has surpassed 86%.
The company said it remains on track to report topline data from the study in Q4.
Shares of the company were up 7.8% in Wednesday's premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.